About briacell therapeutics corp - BCTX
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
BCTX At a Glance
BriaCell Therapeutics Corp.
Bellevue Centre
West Vancouver, British Columbia V7T 2X1
| Phone | 1-604-921-1810 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -26,311,867.00 | |
| Sector | Health Technology | Employees | 17 | |
| Fiscal Year-end | 07 / 2026 | |||
| View SEC Filings |
BCTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.77 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.565 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
BCTX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,547,756.882 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
BCTX Liquidity
| Current Ratio | 5.009 |
| Quick Ratio | 5.009 |
| Cash Ratio | 4.491 |
BCTX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -191.206 |
| Return on Equity | -339.542 |
| Return on Total Capital | -147.151 |
| Return on Invested Capital | -339.542 |
BCTX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |